Union Health Minister JP Nadda flagged off the Jan Aushadhi Raths for the Jan Aushadhi Saptah from March 1 to 7, aiming to open 20,000 Jan Aushadhi centres by the end of 2025. Events during the week will raise awareness about affordable generic medicines. Sanitary pads will also be offered at Rs 1 to promote menstrual hygiene.
from Healthcare/Biotech-Industry-Economic...
Biocon launches diabetes, obesity management drug in UK
Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide. This follows approval from the UK's MHRA, making Biocon the first generics company to gain such approval in a major regulated market.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vB1bDCs
via...
CDSCO revamps NOC process for unapproved drug exports to boost efficiency & reduce manpower pressure
Indian drug regulator CDSCO is streamlining the process for granting No Objection Certificates (NOCs) for unapproved drug exports by moving to blanket, country-specific NOCs based on export history. This change aims to ease manpower pressure and improve regulatory efficiency, reducing annual NOCs significantly.
from Healthcare/Biotech-Industry-Economic...
New NOC process in works for export of unapproved drugs
The Indian drug regulator CDSCO is revamping the process for granting No Objection Certificates (NOCs) for the export of unapproved drugs to reduce manpower pressure and boost regulatory efficiency. Instead of buyer and quantity-specific NOCs, blanket NOCs will be issued based on export history and country approval.
from Healthcare/Biotech-Industry-Economic...
Healthcare experts urge India to rewrite clinical trial rules to boost global market share
Healthcare experts suggest that India could increase its share in the global clinical trials market by learning from countries like China and Australia. India currently holds an 8% share, compared to China’s 29%. Experts emphasize improving regulatory speed, offering incentives, and raising patient awareness for trials. India’s clinical trials market...
AI in healthcare likely to contribute $30 bn to India's GDP by 2025: Report
Artificial Intelligence (AI) in healthcare could boost India's GDP by USD 25-30 billion by 2025, driven by initiatives like the IndiaAI Mission. Despite this, regulatory challenges, limited digital infrastructure, and workforce training gaps hinder faster AI adoption, especially compared to the banking sector.
from Healthcare/Biotech-Industry-Economic...
India's contract drug makers seek government support in China fight
India's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With potential growth to $22-25 billion by 2035, the industry aims to compete globally, but currently faces delays and higher costs compared to Chinese counterparts.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bH8MIAN
via...
Glenmark launches Epinephrine injection in US
Glenmark Pharmaceuticals has launched a generic version of Epinephrine injection multiple-dose vial in the US, gaining 180 days of CGT exclusivity. The injection treats hypotension from septic shock and allergic reactions. Glenmark's product, bioequivalent to BPI Labs' reference drug, adds to their institutional portfolio and achieved annual sales...
India on the verge of becoming clinical trials hub, Parexel executive says
India is poised to become a prominent site for early-stage clinical trials, particularly amid the disruptions caused by the Russia-Ukraine conflict. Parexel plans to increase its Indian workforce by over 2,000 within five years, citing lower costs and growing market potential. However, challenges such as regulatory inconsistencies and awareness regarding...
Zydus launches vaccine for new strain of influenza virus
Zydus Lifesciences introduces India's first quadrivalent influenza vaccine, VaxiFlu-4, for protection against four new virus strains as per WHO recommendations. The vaccine, developed at Zydus's Vaccine Technology Centre in Ahmedabad, has been cleared by the Central Drug Laboratory and aims to address major public health challenges by preventing flu...
No gym? No problem! 7 fun ways to stay fit at home
Skip the gym and stay fit with fun workouts like swimming, hula hooping, aerial yoga, Zumba, stair running, cycling, and exercise videos. These activities boost strength, endurance, and flexibility at home or outdoors!
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E5FOCAa
via IFT...
Indian drugmakers likely to stay competitive despite planned tariffs, Dr Reddy's says
Indian drugmakers, including Dr Reddy's, are confident about maintaining competitiveness in the generic drugs market despite potential U.S. tariffs on pharmaceutical imports. Dr Reddy's MD, GV Prasad, stated that Indian firms are awaiting more details on the tariffs but emphasized that shifting pharmaceutical production to the U.S. is impractical and...
New cases of breast cancer could be up 38 pc by 2050 globally; related deaths by 68 pc: Study
By 2050, breast cancer cases and deaths are expected to rise significantly, particularly in countries with low human development index. Researchers using the GLOBOCAN database found disparities in diagnosis and mortality rates globally. Improvements in early diagnosis and treatment, along with investing in high-quality cancer data, are essential to...
What explains feverish deal-making in India's hospital sector
India's hospital sector is experiencing a surge in deal-making, with KKR acquiring Healthcare Global for $400 million. This trend highlights the growing investor interest in the sector, driven by the increased demand for quality healthcare services. Factors such as medical tourism, government support, and expanding insurance coverage contribute to...
Amgen to invest $200 million in India site, CEO says
Amgen will invest $200 million in its new technology centre in Hyderabad, India, this year, with plans for further investments. The centre, focused on AI and data science for drug development, will employ around 2,000 people by year-end. The announcement coincides with the BioAsia conference, which will feature global pharmaceutical executives.
from...
Opiod row: Aveo Pharma says drug cleared by state authorities; govt says not approved
Aveo also claimed it is not the only company in India manufacturing a similar combination product. A recent BBC investigation report alleged that the "unlicensed addictive" combination was being illegally exported to African nations such as Ghana and Nigeria, leading to a serious public health crisis of opioid addiction.
from Healthcare/Biotech-Industry-Economic...
KKR to buy cancer care hospital chain HCG from CVC for $400 million
KKR acquires a controlling stake in Healthcare Global from CVC Capital Partners for Rs 3466 crore, strengthening its presence in the healthcare sector. The deal gives KKR up to 77% ownership, and Dr. BS Ajaikumar will take on a new role as Non-Executive Chairman.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FA3rGdI
via IFT...
FDA issues show cause notice to pharma firm in Palghar for illegal export of opioids
Palghar's Food and Drug Administration took legal action against Aveo Pharmaceuticals for alleged illegal opioid export after a BBC report revealed Tapentadol and Carisoprodol were being exported to Africa for recreational use. Authorities raided the company, seized stock, stopped production, and issued a show cause notice, following the Central government's...
India bans production of two drugs ‘behind’ opioid crisis in West Africa
The Drug Controller General of India has banned the production of tapentadol and carisoprodol after they were found to be illegally exported to African nations. These drugs, produced by Aveo Pharma, have contributed to the opioid addiction crisis in countries like Nigeria and Ghana.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uow3dQy
via...
Govt steps up inspections at pharma units to ensure quality
Government authorities have conducted risk-based inspections at over 500 pharmaceutical manufacturing units since 2022 to enhance the quality of locally produced medicines and prevent the sale of spurious drugs. Over 400 actions have been taken against units failing to meet quality standards, and inspections are expected to continue.
from Healthcare/Biotech-Industry-Economic...
Dr Agarwal's Eye Hospital appoints Sachin Tendulkar as its brand ambassador
Dr Agarwal's Eye Hospital has appointed cricket legend Sachin Tendulkar as its brand ambassador. The hospital has been conducting 100 free eye surgeries annually as a tribute to Tendulkar's 100 centuries, and Tendulkar will now help promote awareness about eye care through this collaboration.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q1GLXEW
via...
Apollo Hospitals calls for liberal visa policy to boost medical tourism
Apollo Hospitals' Joint Managing Director Sangita Reddy highlights the need for a liberal visa policy to boost India's medical tourism sector, emphasizing the government's 'Heal in India' initiative. The healthcare provider plans to add around 3,000 beds and invest nearly Rs 6,000 crore for expansion over five years.
from Healthcare/Biotech-Industry-Economic...
Indian drugmakers can retain US dominance even with tariffs, says industry body
Indian pharmaceutical companies are expected to maintain their strong presence in the U.S. generic drug market despite possible high tariffs from President Donald Trump. The Pharmaceuticals Export Promotion Council of India believes these companies' competitiveness will help them navigate the new environment, although higher tariffs may squeeze the...
Pfizer board approves marketing, supply pact with Mylan for two brands
Pfizer Ltd's board has approved a five-year marketing and supply agreement with Mylan Pharmaceuticals for the brands Ativan and Pacitane, targeting the treatment of anxiety disorders and Parkinsonism. The partnership leverages Mylan's expertise in the central nervous system therapy area to enhance product distribution and engagement with neurologists...
India, the 'pharmacy of the world' banks on bilateral talks for relief from planned US tariffs
Indian drugmakers are seeking bilateral discussions with the U.S. to avoid President Donald Trump’s proposed 25% tariff on pharmaceutical imports, according to the Indian Pharmaceutical Alliance (IPA). The U.S. is India's largest market, accounting for $8.7 billion (31%) of total pharma exports in fiscal 2024.
from Healthcare/Biotech-Industry-Economic...
India becoming an attractive option for global pharmaceutical supply chain: Macquarie Report
India's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulatory support. The industry's growth could reach a high-teens CAGR due to factors like the US Biosecure Act, potentially pushing it to USD 22 billion by 2030.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J4TldtY
via...
Not scared of Trump's threats? India's drug, auto exporters see limited impact of US tariffs
Indian exporters believe that US President Trump's proposed tariffs on automobile and pharmaceutical imports will not significantly affect their competitiveness. Industry leaders suggest adjusting domestic policies to mitigate any potential impact. Indian pharmaceuticals and auto components are expected to remain resilient despite the potential for...
Generic pain, margin loss: Drug companies may find it hard to adjust with Trump's tariff plans
US President Trump's 25% tariff plan on pharmaceuticals jeopardizes Indian pharma exports, making generics pricier and impacting margins. Indian companies and stock markets brace for the impact, as India dominates with 30% of exports to the US. Firms may face challenges balancing costs and profit margins.
from Healthcare/Biotech-Industry-Economic...
Tata Group to invest Rs 500 crore in Breach Candy Hospital Expansion
Tata Group will invest Rs 500 crore in Breach Candy Hospital, becoming its largest financial backer. This will allow Tata Group to add three representatives to the board and support infrastructure and technology improvements. Chairman N Chandrasekaran will replace Deepak Parekh as chairman of Breach Candy Hospital Trust from October 2025, while Parekh...
Pharma market in good health; lifestyle diseases may be rising
The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the therapy segment, the data showed. According to Pharmarack, emerging molecules like vericiguat, finerenone and midodrine also posted robust growth.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vsrhiJD
via IFT...
Practo appoints Jagnoor Singh as COO
Practo has appointed Jagnoor Singh as its new COO to boost growth and refine processes. With 16 years of experience at top firms, Singh will collaborate with CEO Shashank ND to expand into new markets and enhance existing ones, aiming to make healthcare more accessible and affordable.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9PF1sY0
via...
SMT appoints Bhargav Kotadia as chief executive officer
Samara Capital-backed Sahajanand Medical Technologies has named Bhargav Kotadia as CEO and Jose Calle Gordo (‘Pepe’) as chairman, effective April 1. Kotadia replaces Ganesh Sabat, while founder Dhirajlal Kotadia becomes chairman emeritus. The new leadership aims to drive SMT’s growth in cardiovascular technologies, focusing on delivering high-quality...
Glenmark, FDC recall products in US due to manufacturing issues: USFDA
Glenmark Pharmaceuticals and FDC Ltd are recalling some products in the US market. Glenmark is recalling certain strengths of Carvedilol tablets due to impurity issues. FDC Ltd is recalling bottles of glaucoma medication Timolol Maleate due to defective containers. Both recalls were initiated in January 2025 to ensure safety.
from Healthcare/Biotech-Industry-Economic...
Aurobindo Pharma to commence supplies to Europe from China plant in April
Aurobindo Pharma will start supplying products from its new China facility to Europe by April 2024. The company is ramping up production after receiving European regulatory approvals. Plans to enter the US market are also in progress. Aurobindo expects significant revenue growth from this facility over the next two to three years.
from Healthcare/Biotech-Industry-Economic...
MSD Pharma, Delhi Capitals partner to create awareness about cervical cancer prevention
MSD Pharmaceuticals and Delhi Capitals have partnered to raise cervical cancer prevention awareness in India. The women's T20 team will display this message on their jerseys during matches. The initiative aims to reduce stigma, provide information accessibility, and promote preventive health measures. Cervical cancer remains a major issue in India...
'Discover and Make in India' to drive innovation in pharma, says Dilip Shanghvi, Founder & Managing Director, Sun Pharmaceutical Industries
India has established itself as a global leader in pharmaceutical production, with potential for further growth through increased investment in drug discovery. Companies like Sun Pharma are already making strides with innovative products and clinical trials, promising a future where India can contribute significantly to global healthcare.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences inks licensing pact with Zhuhai for cancer drug
Zydus Lifesciences' subsidiary partners with Zhuhai Beihai Biotech to market Beizray, a cancer drug, in the US. Zhuhai will handle manufacturing while Zydus will commercialize the product, targeting breast cancer and other types. The partnership includes milestone payments and profit-sharing, tapping into a market of around 531,000 units annually.
from...
Glenmark launches generic ophthalmic solution in US market
Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. The product matches Upjohn US LLC's Xalatan Ophthalmic Solution, which had annual sales of USD 113.5 million. This launch reflects Glenmark's growing ophthalmic portfolio and commitment to quality solutions.
from...
KKR set to buy cancer chain HCG
KKR is set to acquire a 51% stake in Healthcare Global Enterprises from CVC Capital Partners. The $3,128 crore deal includes an open offer for an additional 26%. HCG's founding family will retain 10.87%, while the company's growth trajectory and expanded capabilities are expected post-acquisition.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PjabrcN
via...
India, Indonesia ink milestone pact for quality assurance in traditional medicine: Ayush Minister
The Union Minister of State (Independent Charge), Ministry of Ayush, Prataprao Jadhav, stated that the MoU exchanged between India and Indonesia in the field of traditional medicine quality assurance between Pharmacopoeia Commission for Indian Medicine & Homeopathy, Ministry of Ayush and Indonesian Food and Drug Authority.
from Healthcare/Biotech-Industry-Economic...
Pharma companies must file compliance strategy
Drugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and medium manufacturers, with a turnover of less than ₹250 crore, have until December 31 to comply. They need to submit their upgrade plans within three months.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y3BVLIr
via...
Zydus Lifesciences in pact with Synthon for specialty oncology product in US
Zydus Lifesciences has signed an exclusive agreement with Synthon for the development and commercialisation of a novel oncology product, focusing on reducing pill burden and improving patient compliance. Synthon will handle development and manufacturing, while Zydus will oversee NDA submission and marketing in the US by 2026.
from Healthcare/Biotech-Industry-Economic...
Govt extends Schedule M implementation deadline till year-end for small, medium pharma firms
The implementation of revised Schedule M for good manufacturing practices has been conditionally extended to December 31, 2025, for small and medium pharmaceutical firms with turnover of Rs 250 crore or less. These firms must submit an upgrade plan by February 11, 2025, to qualify for the deadline extension. The updated regulations aim to enhance product...
Biovet's new vax developed to treat skin disease of livestock gets regulator's license
Biovet has secured a license from CDSCO for Biolumpivaxin, the world's only marker vaccine for Lumpy Skin Disease in cattle and buffaloes. Developed with the DIVA concept, it ensures high safety and efficacy while distinguishing between infected and vaccinated animals, a crucial step toward India's self-reliance in veterinary healthcare.
from Healthcare/Biotech-Industry-Economic...
Over 3k brands hit pharma mkt, cancer drug tops in sales
India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the top-seller, reflecting a rise in cancer cases. Enhertu, exempted from customs duty, has significantly contributed to AstraZeneca's sales, highlighting the growing demand for innovative cancer treatments.
from Healthcare/Biotech-Industry-Economic...
Biocon betting big on new product launches for growth
Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrates development, production, distribution, and market deployment. Biocon Biologics has acquired Viatris' global biosimilars business, boosting revenue. The company is building a strong brand presence globally, especially...
Bajaj dynasty said to earmark Rs 10,000 crore for hospital chain
Bajaj Group earmarks 100 billion rupees ($1.1 billion) to establish a chain of affordable, high-class hospitals across India. This move aligns with the nation's growing healthcare needs and increased insurance coverage. Led by Nirav Bajaj, this initiative marks the conglomerate's new venture amid its diversified portfolio, including Bajaj Auto and...
India's Pharma market to expand 2.4 times over next 5 years, share in global market to hit 5 pc: Report
India's pharmaceutical industry is set to grow significantly, with its share in the global market expected to reach 5% by 2030. Currently valued at USD 55 billion, the market is projected to hit up to USD 130 billion, driven by strong domestic demand and increasing global exports.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0zHfUdq
via...
NPPA asks retailers to display drug prices on websites
The National Pharmaceutical Pricing Authority (NPPA) will take action if the pharmacies fail to comply with the diktat, it said in an order. It may be noted that the online pharmacies and other online platforms selling medicines were not displaying the prices of drugs, firmly refusing to do so citing extract from the Para 24 of the Drugs (Price Control)...
Sanofi Healthcare gets marketing authorisation for cGVHD drug
Sanofi Healthcare India has obtained marketing authorization for Rezurock, a drug for treating Chronic graft versus host disease (cGVHD), a condition that occurs after allogeneic stem cell transplants. The drug, approved by USFDA and CDSCO, offers a new treatment option for patients over 12 years old after other treatments have failed.
from Healthcare/Biotech-Industry-Economic...
Glenmark, Cosmo get MHRA nod for acne treatment medication
Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment for patients aged 12 and older in the UK. Glenmark licensed the product from Cosmo for distribution in Europe and South Africa, aiming to improve the quality of life for those suffering from acne, which affects a significant portion...
Rashmi Saluja's re-appointment to REL board fails to get shareholders' stamp
Rashmi Saluja's reappointment to Religare Enterprises' board was overwhelmingly rejected by shareholders, with 97.53% voting against it. Despite Saluja's refusal to step down, the resolution was blocked, and the Delhi High Court affirmed that executive directors must retire by rotation as per the Companies Act.
from Healthcare/Biotech-Industry-Economic...
India's CDMO market set to double by 2028 amid Asia's healthcare boom
India's CDMO market is set to grow from USD 7 billion to USD 14 billion by 2028. This growth is driven by its strong stance in API manufacturing and cost advantages over China. Global pharmaceutical companies are diversifying supply chains to India. The broader APAC healthcare sector is also expanding rapidly, supported by rising income levels.
from...
Pharma exports expected to double to $65 billion by 2030: Report
India's pharmaceutical exports are set to reach USD 65 billion by 2030 and USD 350 billion by 2047, placing India among the top five global exporters by diversifying its product range. The report highlights the need for innovation, quality focus, and collaboration between the government and private sector to achieve this growth, emphasizing specialty...
What are nutraceuticals and why are they gaining popularity in India
Nutraceuticals in India are gaining popularity due to rising health awareness, an increase in lifestyle diseases, and a shift toward natural products. The market is expected to grow significantly, driven by government initiatives, increased disposable incomes, and the expansion of online retail models.
from Healthcare/Biotech-Industry-Economic Times...
Alkem Labs acquires two companies specialising in skin care, medtech to bolster domestic business
Alkem Laboratories has announced two strategic acquisitions totaling Rs 287 crores to strengthen its domestic market presence. The company will acquire Adroit Biomed for Rs 140 crore and Bombay Ortho Industries for Rs 147 crore. These acquisitions will diversify Alkem's portfolio and meet growing market demands.
from Healthcare/Biotech-Industry-Economic...
IHH Healthcare seeks damages of upto Rs 10,930 cr from Daiichi Sankyo for obstructing open offer for Fortis
IHH Healthcare is seeking up to Rs 10,930 crore in damages from Daiichi Sankyo for allegedly obstructing NTK's acquisition of Fortis Healthcare. IHH announced that NTK has submitted an additional claim with an expert report to quantify the damages. The dispute stems from a 2018 open offer block by Daiichi's contempt plea against Fortis founders.
from...
Dr Reddy's unit ties up with Shanghai Henlius Biotech
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Darzalex. Henlius will manage development and manufacturing, receiving up to $131.6 million. Dr Reddy's gains exclusive rights to market the drug in the US and Europe.
from Healthcare/Biotech-Industry-Economic Times...
GBS patient treated in Gurugram, cases rise in Pune
Healthcare authorities are closely monitoring the outbreak of Guillain-Barre Syndrome (GBS) in Pune as cases rise to 158, with five deaths suspected in Maharashtra. Doctors report instances of muscle weakness and dysfunction, primarily affecting the younger population, and are coordinating efforts with the Centre to control the spread.
from Healthcare/Biotech-Industry-Economic...
ICMR initiates process of vaccine against avian influenza
The ICMR has launched efforts to develop a human vaccine against the highly-pathogenic avian influenza H5N1. This virus poses a significant public health risk due to its high mortality rate and potential to cause global pandemic. Recent outbreaks highlight the urgency of vaccine development for better preparedness.
from Healthcare/Biotech-Industry-Economic...
Budget 2025: 'Customs waiver on life-saving drugs won't benefit most patients'
Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high prices maintained by patent monopolies. Activists call for generic production by Indian manufacturers and GST exemption on locally available drugs to effectively reduce prices and provide affordable treatment.
from...
Want youthful skin? Eat these 5 anti-aging foods daily - here's why
Aging is a natural process, but the right diet can slow down its effects, keeping your skin youthful and vibrant. Here are five anti-aging foods to include in your daily routine:
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IckKz5O
via IFT...
Sun Pharma elevates Aalok Shanghvi as COO
Sun Pharma, India's largest drugmaker, has designated Aalok Shanghvi as Chief Operating Officer. Aalok, the son of promoter Dilip Shanghvi, has held various strategic roles since joining in 2006 and has been a whole-time director since June 2023. Sun Pharma reported revenue of ₹48,496 crore for FY24, with a market valuation of ₹4.17 lakh crore.
from...
World Cancer Day 2025: 6 facts you probably didn't know about cancer
Observed every year on February 4th, World Cancer Day is a global initiative to raise awareness about cancer prevention, early detection, and treatment. It unites individuals, communities, and organizations to highlight the challenges of cancer and encourage action.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xD5R3Nq
via IFT...
Making India a global hub for healthcare: Suneeta Reddy, MD, Apollo Hospitals
This year's budget focuses on improving healthcare in India, with initiatives like 200-day care chemo centres, increasing medical seats, and promoting medical tourism. The government aims to encourage discretionary spending by boosting disposable income, facilitating better access to quality healthcare, and simplifying regulations across sectors.
from...
Budget 2025 impact: Pharma and Healthcare
The Budget 2025 has indirect positive impacts on pharma and healthcare sectors with the addition of 36 lifesaving drugs attracting a 5% customs duty. The budget plans to add 75,000 medical college seats over five years and establish 200 day care cancer centres by FY26.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZW7dvIu
via IFT...
Union Budget 2025: Key healthcare moves for cancer treatment, gig workers, & medical education
Finance Minister Nirmala Sitharaman's Union Budget 2025-26 includes initiatives such as establishing Daycare Cancer Centres in all district hospitals, providing healthcare coverage for gig workers under PM-JAY, expanding medical education seats by 10,000, and ensuring broadband connectivity to all government schools and healthcare centres, particularly...